Technology Appraisal Committee Meeting (Committee A)

**Zoom**

## Minutes: Confirmed

## Date and Time: Tuesday 12 May 2020, 10:00 – 13:45

### Present:

1. Dr Jane Adam (Chair) Present for all notes
2. Dr Brian Shine (Vice Chair) Present for all notes
3. Dr Peter Baker Present for all notes
4. Mr Richard Ballerand Present for all notes
5. Dr Andrew Champion Present for all notes
6. Dr Steve Edwards Present for all notes
7. Dr Rita Faria Present for all notes
8. Dr Khalida Ismail Present for all notes
9. Professor G.J. Melendez-Torres Present for all notes
10. Mrs Becky Pennington Present for all notes
11. Ms Pamela Rees Present for all notes
12. Dr Mohit Sharma Present for all notes
13. Mr Stephen Sharp Present for all notes
14. Dr Alice Turner Present for all notes
15. Mr Min Ven Teo Present for all notes
16. Dr Roger Whittaker Present for all notes

**In attendance:**

* Janet Robertson, Associate Director, NICE, Present for all notes
* Thomas Feist, Project Manager, NICE, Present for all notes
* Marcia Miller, Administrator, NICE, Present for all notes
* Zoe Charles, Technical Adviser, NICE, Present for all notes
* Albany Meikle, Technical Analyst, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Jenna Dilkes, Programme Manager, NICE, Present for all notes
* Natalie Spray, Project Manager, NICE, Present for all notes
* Mandy Brereton, Assistant Project Manager, NICE, Present for all notes
* Thomas Strong, CDF Team, NICE, Present for all notes
* Claire Hawksworth, CDF Team, NICE, Present for all notes
* Sridhar Chaganti, Clinical Expert, Consultant Haematologist, Present for notes 1 to 5
* Kate Cwynarski, Clinical Expert, Consultant Haematologist, Present for notes 1 to 5
* Prof Peter Clark, Cancer Drugs Fund Clinical Lead, Present for notes 1 to 8
* Nigel Armstrong, KSR, Evidence Review Group, Present for notes 1 to 5
* Hannah Penton, KSR, Evidence Review Group, Present for notes 1 to 5
* Isaac Corro Ramos, KSR, Evidence Review Group, Present for notes 1 to 5

### Non-public attendees:

* Emma Douch, Technical Analyst, NICE, Present for all notes
* Yelan Gou, Technical Analyst, NICE, Present for all notes
* Oswin Jackson, Digital Services, NICE, Present for all notes
* Bijal Joshi, Programme Manager, NICE IP, Present for notes 4 to 8
* Nick Lowe, Digital Services, NICE, Present for all notes
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* Sophie McHugh, Administrator, NICE, Present for all notes
* George Millington, Assistant Technical Analyst, Present for all notes
* Sandra Robinson, Corporate Office Coordinator, NICE, Present for notes 1 to 4
* Faye Sheldon, Technical Analyst, NICE, Present for all notes
* Ria Skelton, Editor, NICE, Present for all notes
* Gemma Smith, Coordinator, NICE, Present for all notes

## Notes

### Any other Business

1. None

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Tuesday 24 March 2020.

## Appraisal of polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B cell lymphoma [ID1576]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Roche.
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.

	1. Kate Cwynarski declared a direct financial interest as she has received financial support from Roche to attend conferences and has attended advisory boards for Roche.
		1. It was agreed that this declaration would not prevent her from participating in this section of the meeting.
	2. Sridhar Chaganti declared a direct financial interest as he has received honoraria for advisory boards for Roche.
		1. It was agreed that this declaration would prevent him from participating in this section of the meeting.
	3. No further conflicts of interest were declared for this appraisal.
3. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2a – Closed session (members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.

### Part 2b – Closed session (company representatives, clinical and patient experts, ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based consensus.
3. The committee asked the NICE technical team to prepare a document in line with their decisions.